Abstract:Krabbe disease (KD) is an autosomal recessive lysosomal storage disorder caused by loss–of–function mutations in the GALC gene, which encodes for the enzyme galactosylceramidase (GALC). GALC is crucial for myelin metabolism. Functional deficiency of GALC leads to toxic accumulation of psychosine, dysfunction and death of oligodendrocytes, and eventual brain demyelination. To date, 46 clinically–relevant, pathogenic GALC missense mutations (MMs) have been identified in KD patients. These MMs are present in ~70% of KD cases reported over 8 published studies between 1996 – 2019. However, the mechanisms by which these MMs lead to GALC functional deficiency and their correlations with clinical phenotype remain poorly understood. To address this, we generated a GALC–knockout human oligodendrocytic cell line (MO3.13/ GALC–KO) using CRISPR–Cas9 method to assess GALC function and GALC secretion. We evaluated 5 polymorphic and 31 clinically–relevant MM variants (MMVs) using transient expression assays. Our results showed that 26 MMVs, including 10 co–variants with p.I562T, reduced GALC activity by 92% – 100% compared to wildtype GALC (WT–GALC). MMVs from infantile-onset KD patients produced < 2% of WT activity, whereas those associated with juvenile– and adult–onset cases retained up to 7% of WT activity. Residual GALC activity was correlated with mature, lysosomal GALC protein levels (Pearson r = 0.93, P<0.0001). Many low–activity MMVs did not correspondingly impair GALC secretion. Twenty–one of the 26 low–activity MMVs showed a 21% – 100% reduction in sec–GALC levels, indicating varying degrees of GALC mis–trafficking among these variants. Importantly, GALC activity among MMVs strongly correlates with clinical disease severity, based on the age of symptom onset in patients with either homozygous MM (Pearson r = 0.98, P<0.0001, n = 7) or compound heterozygous (Pearson r = 0.94, P<0.0001, n = 12) MM–null mutation genotypes. Thus, our data suggests that GALC activity could serve as a prognostic disease indicator under specific experimental conditions. We further investigated the impact of pathogenic MMVs on psychosine accumulation, a key biomarker for KD. Psychosine levels were 21–fold higher in mock control cells compared to WT–GALC transfected cells (mock = 0.349 pmol/mg, WT–GALC = 0.016 pmol/mg), but negatively correlated with GALC activity among pathogenic MMVs (Pearson r = –0.63, P < 0.01, n = 15). Although psychosine levels were higher in most MMVs associated with infantile–onset KD, no significant correlations with clinical onset were detected. Overall, our study provides a comprehensive quantitative analysis of the functional deficits and mis–trafficking associated with clinically–relevant GALC MMVs, enhancing our understanding of the molecular genetics and genotype–phenotype correlations of the GALC gene in Krabbe disease.

Development and Validation of Leukocyte Enzyme Activity Assay by LC-MS/MS for Diagnosis of Krabbe Disease and Other Lysosomal Storage Diseases

Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease

Expression study of Krabbe Disease GALC missense variants — Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels

Validation of high-sensitivity assays to quantitate cerebrospinal fluid and serum β-galactosidase activity in patients with GM1-gangliosidosis

Natural history of Krabbe disease – a nationwide study in Germany using clinical and MRI data

Late‐onset Krabbe disease presenting as spastic paraplegia – implications of GCase and CTSB/D

Synthetic Sulfogalactosylceramide (sulfatide) and Its Use for the Mass Spectrometric Quantitative Urinary Determination in Metachromatic Leukodystrophies

Krabbe disease: New hope for an old disease

Splicing mutations of GALC in adult patient with adult-onset Krabbe disease: case report and review of literature

Novel GALC Mutations Cause Adult-Onset Krabbe Disease With Myelopathy in Two Chinese Families: Case Reports and Literature Review

Efficacy and Safety of a Krabbe Disease Gene Therapy

Infantile Krabbe disease (0–12 months), progression, and recommended endpoints for clinical trials

CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease

A new diagnostic assay for glycogen storage disease type II in mixed leukocytes

A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease

Achieving Congruence among Reference Laboratories for Absolute Abundance Measurement of Analytes for Rare Diseases: Psychosine for Diagnosis and Prognosis of Krabbe Disease

LC-MS/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: A novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease

Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor

A multiplexed targeted method for profiling of serum gangliosides and glycosphingolipids: application to GM2-gangliosidosis

A novel brain-penetrant oral UGT8 inhibitor decreases in vivo galactosphingolipid biosynthesis in murine Krabbe disease

Quantification of N-acetyl-l-aspartate in dried blood spots: A simple and fast LC-MS/MS neonatal screening method for the diagnosis of Canavan disease